Related Experiment Video
Updated: May 18, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Association between cytochrome P450 promoter polymorphisms and ischemic stroke
Su Kang Kim1, Sung-Vin Yim, Byung-Cheol Lee
1Kohwang Medical Research Institute;
Experimental and Therapeutic Medicine
|September 13, 2012
Summary
Genetic variations in cytochrome P450 (CYP) genes like CYP11B2, CYP2E1, and CYP7A1 are linked to ischemic stroke (IS) risk. Specific single nucleotide polymorphisms (SNPs) show associations with IS and related conditions like diabetes and smoking.
Area of Science:
- Genetics
- Pharmacogenomics
- Neurology
Background:
- The cytochrome P450 (CYP) superfamily comprises numerous genes crucial for metabolic and biosynthetic processes.
- Understanding genetic predispositions, such as polymorphisms in CYP genes, is vital for identifying individuals at higher risk for diseases like ischemic stroke (IS).
Purpose of the Study:
- To investigate the association between specific single nucleotide polymorphisms (SNPs) in selected Cytochrome P450 (CYP) genes and the risk of ischemic stroke (IS).
Main Methods:
- Six single nucleotide polymorphisms (SNPs) from CYP11B2, CYP17A1, CYP2B6, CYP2C9, CYP2E1, and CYP7A1 genes were genotyped in 121 IS patients and 321 controls.
- Genetic data were analyzed using SNPStats and SPSS 18.0 with multiple logistic regression models.
Main Results:
- The rs179998 SNP of CYP11B2 showed a significant association with IS risk (p=0.0336).
- The rs3813867 SNP of CYP2E1 was associated with smoking in IS patients (p=0.0336).
- SNPs rs1799998 in CYP11B2 and rs3808607 in CYP7A1 were linked to diabetes mellitus in IS patients (p<0.05).
Conclusions:
- Polymorphisms in CYP11B2, CYP2E1, and CYP7A1 genes are associated with ischemic stroke in the studied population.
- These findings highlight potential genetic markers for IS risk, though further research is needed to confirm their biological significance.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:15Ischemic Stroke l: Introduction
Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.